Increased Serum Levels of the IL‐33 Neutralizing sST2 in Limited Cutaneous Systemic Sclerosis

• DOI: 10.1111/sji.12317
• Publication Date: 2015-06-20T01:09:15Z
• Authors: A. Wagner; M. Köhm; A. Nordin; E. Svenungsson; J.M. Pfeilschifter; H. H. Radeke
• Keywords: Pathogenesis; Iloprost; Pathophysiology; Scleroderma (fungus)

Abstract The pathophysiology of both limited cutaneous systemic sclerosis (lcSSc) and diffuse SSc (dcSSc), representing two subtypes an autoimmune disease the connective tissue, is still enigmatic. Life‐limiting, progressive fibrotic changes as a consequence vasculopathy autoimmunity are characteristic in varying extent for lc SS c dc c. Previously, increased IL ‐33 serum concentration early phase patients elevated tissue expression its receptor, ST 2L, on endothelial cells ( EC ) were described. While suggested biomarker diseases, example liver fibrosis, role soluble 2 sST 2) pathological processes contribution to vascular fibrosis has not been investigated. Here, we showed that late (lc c) compared with shorter duration or subtype We demonstrated 2, ‐33, significantly over 9 years. Soluble was healthy controls skin involvement than Furthermore, observed levels lowered by iloprost (prostacyclin) treatment. After 5 days infusion, fell 6 7 patients. Therefore, only like propose but moreover, suggest pathogenesis may be exploited therapeutically.